Pioneering therapies for oncogene-driven cancers
Haptena Therapeutics: where precision oncology meets next-generation immune innovation.
Our mission is to bridge the precision of targeted therapies and the transformative potential of immune-based treatments to deliver more durable options for patients with some of the most challenging tumors.
Haptena is a biotech company founded in 2025 by Professors Chiara Ambrogio and Roberto Chiarle, with the goal of advancing next-generation immunotherapies for genetically defined cancers.
Many cancers caused by oncogenes continue to be inadequately treated with existing therapies. Targeted therapies offer precision, although duration of response should still be improved; immunotherapies demonstrated profound efficacy, but struggle to be applied to genetically complex cancers.
Our programs aim to integrate the precision of targeted therapies with the power of immune-based approaches, starting with KRAS-driven tumors.
